MemorialCare Research Center Contact Form
For further information about this study or to express your interest in this study, please fill out and submit this form.
18 years and older
Male or Female
This study is being conducted to evaluate the efficacy and safety of durvalumab adjuvant therapy compared to placebo in patients with completely resected stage II-III NSCLC who have undergone curative intent therapy (complete resection ± neoadjuvant and/or adjuvant therapy), and who become MRD+ during a 96-week surveillance period.